Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

INTRODUCTION: Upfront next-generation sequencing (NGS) in patients with metastatic NSCLC has been associated with cost savings and shorter time-to-test results in the United States. Nevertheless, this may not apply in jurisdictions where the prevalence of patients with actionable mutations, cost of...

Descripción completa

Detalles Bibliográficos
Autores principales: Loong, Herbert H., Wong, Carlos K.H., Chan, Catherine P.K., Chang, Andrea, Zhou, Zheng-Yi, Tang, Wenxi, Gibbs, Meaghan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919283/
https://www.ncbi.nlm.nih.gov/pubmed/35295964
http://dx.doi.org/10.1016/j.jtocrr.2022.100290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919283/
https://www.ncbi.nlm.nih.gov/pubmed/35295964
http://dx.doi.org/10.1016/j.jtocrr.2022.100290

Ejemplares similares